Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

EIKN

Eikon Therapeutics Inc

Feb 06 • 04:00PM ET

14.50

-0.50 -3.33 %

Healthcare • Biotechnology • USA • NASD

Feb 06, 4:20 PMEikon Therapeutics discloses that it has amended its certificate of incorporation and bylaws today in connection with the closing of its IPO.

Held by: BMED

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	50.45M	Perf Week	-
Market Cap	731.53M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	1.52B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-3.33%
Book/sh	-11.34	P/C	3.32	EPS next 5Y	-	ROE	-	52W High	17.40 -16.67%	Perf Year	-
Cash/sh	4.37	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	14.36 0.94%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.89	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.04	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	4.04	EPS Q/Q	-	SMA20	-1.69%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.86	Sales Q/Q	-	SMA50	-1.69%	Rel Volume	0.17	Prev Close	15.00
Employees	-	LT Debt/Eq	0.82	Earnings	-	SMA200	-1.69%	Avg Volume	4.90M	Price	14.50
IPO	Feb 05, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	831,555	Change	-3.33%

Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
Feb-05-26 07:23PM	This Mobile App Marketing Firm Is Holding Off an IPO for Now (Barrons.com)
Feb-04-26 07:59PM	Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level, supporting targeted treatment development. The company's approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Capital Management IV	10% Owner	Feb 04 '26	Buy	18.00	55,555	999,990	1,318,983	Feb 06 07:37 PM
FRAZIER KENNETH C	Director	Feb 04 '26	Buy	18.00	111,111	1,999,998	111,111	Feb 06 06:33 PM
Wolfe Josh	Director	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:27 PM
Lux Venture Partners V, LLC	10% Owner	Feb 04 '26	Buy	18.00	277,776	4,999,968	138,888	Feb 06 06:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EIKN

Eikon Therapeutics Inc

Upgrade your FINVIZ experience